found that ad libitum KD treatment down-regulated hypoxia-related protein (hypoxia-inducible factor 1, HIF-1α) and growth-driven proteins (NF-κB, and VEGF receptor-2), when assessing the effect of the KD on cancers growth and progression using a mouse model (134) (Figure 4C). Here, NFKB1 is linked to cancer.